Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Recent Research on Diabetes Mellitus, Non-Hodgkin Lymphoma Link

October 18, 2019
By Leanne Marcello, MS
News
Article

After conflicting opinions over the years, a study published in the journal Hematology explores the association between diabetes mellitus non-hodgkin lymphoma.

After conflicting opinions over the years, a study published in the journal Hematology found a definitive association between diabetes mellitus (DM) and a greater risk of non-hodgkin lymphoma (NHL).

Diabetes mellitus is a leading public health threat worldwide, and one that affects 3–4% of adults globally. DM contributes to as many as 1.3 million deaths around the globe each year. Scientists predict that DM will be among the five leading disease burdens worldwide by the year 2030. It has previously been established in myriad research that diabetes mellitus is a significant risk factor in the development or prognosis of many disease processes. A diagnosis of DM puts people at risk for cardiovascular disease, dementia, kidney failure, liver ailments, and a number of solid tumors, including those of the pancreas, colon, liver, breast, ovaries, endometrium, lung, and prostate. In addition, prior meta-analyses suggest that DM patients might be at greater risk for one or more hematologic malignancies as well.

Non-Hodgkin lymphoma is a fairly prevalent blood cancer that arises from lymphocytes. It is found more often in developed countries and represents 4.3% of all new cancer diagnoses in the United States. In recent years, it has ranked as high as 7th in males and 6th in females as leading cancer. NHL has been on the rise in Western countries in the new century, particularly in the white, male, and elderly populations. Researchers have labored to identify the pathophysiology of NHL, but they have yet to narrow down its causes.

Although a recent study in Japan, showed that males with DM were at greater risk of developing NHL, while females were not, the relationship between DM and lifetime risk of NHL is something researchers have not yet come to an agreement on either.

In this meta-analysis of cohort studies, the authors investigated the association between the two.

The authors conducted a systematic search of PubMed, the Cochrane Library, and EmBase to identify eligible studies that began no earlier than September of 2018, which led them to 13 cohort studies with a combined total of 9024761 participants. THe researchers discovered that DM was repeatedly associated with an increased risk of NHL (RR = 1.15, 95%CI: 1.02, 1.30, P = .03). Conducting analyses of subgroups, the authors found that DM was most frequently associated with patients under the age of 60 years (RR = 1.65, 95%CI: 1.31, 2.09, P < .0001), follow-up duration within 8 years (RR = 1.23, 95%CI: 1.02, 1.48, P = .03), and studies adjusted for body mass index (RR = 1.35, 95%CI: 1.01, 1.79, P = .04). The investigators also determined that men with DM were more likely to develop NHL than women were (RR = 1.31, 95%CI: 1.04, 1.65, P = .02).
The study authors concluded that patients with DM patients are at substantially greater risk of developing NHL in comparison with nondiabetics, and that male patients with diabetes have the greater likelihood in comparison with females. Further studies should be conducted to rule out miscellaneous factors that may have skewed results.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content

The complete response (CR) rate was 51.4% with M-Pola vs 24.3% with R-GemOx, respectively.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

Tim Cortese
September 11th 2025
Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
September 11th 2025
Podcast

The safety and cytokine release syndrome profiles of mosunetuzumab were manageable in patients with previously untreated marginal zone lymphoma.

Mosunetuzumab Exhibits Meaningful Responses in Untreated MZL

Roman Fabbricatore
September 11th 2025
Article

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
September 11th 2025
Podcast

Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703

Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703

American Society for Transplantation and Cellular Therapy
September 11th 2025
Article

Reprogramming the Neuroblastoma Tumor Immune Microenvironment to Enhance GPC2 CAR T-cells

Reprogramming the Neuroblastoma Tumor Immune Microenvironment to Enhance GPC2 CAR T-cells

American Society for Transplantation and Cellular Therapy
September 11th 2025
Article
Related Content

The complete response (CR) rate was 51.4% with M-Pola vs 24.3% with R-GemOx, respectively.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

Tim Cortese
September 11th 2025
Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
September 11th 2025
Podcast

The safety and cytokine release syndrome profiles of mosunetuzumab were manageable in patients with previously untreated marginal zone lymphoma.

Mosunetuzumab Exhibits Meaningful Responses in Untreated MZL

Roman Fabbricatore
September 11th 2025
Article

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
September 11th 2025
Podcast

Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703

Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703

American Society for Transplantation and Cellular Therapy
September 11th 2025
Article

Reprogramming the Neuroblastoma Tumor Immune Microenvironment to Enhance GPC2 CAR T-cells

Reprogramming the Neuroblastoma Tumor Immune Microenvironment to Enhance GPC2 CAR T-cells

American Society for Transplantation and Cellular Therapy
September 11th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.